Story
Braveheart Bio Stock Jumps 68% in Nasdaq Debut After $382.5M IPO

Shares of Braveheart Bio Inc. (NASDAQ: BRVE) surged in their public market debut on Thursday, closing 68% above their initial public offering price after the company raised $382.5 million.
Trading Debut Details
The stock began trading in New York at $30.20 per share, a significant premium to its IPO price of $18. The strong investor reception pushed the company's market valuation to $2.13 billion based on its outstanding shares, according to a report from Investing.com.
The offering was managed by a syndicate of underwriters that included Goldman Sachs Group Inc., Jefferies Financial Group Inc., and Toronto-Dominion Bank, among others. Braveheart Bio now trades on the Nasdaq Global Market under the ticker symbol BRVE.
Company and Pipeline
Braveheart Bio, established in 2024, is a clinical-stage biopharmaceutical firm focused on developing treatments for cardiovascular diseases. Its primary asset is the drug candidate BHB-1893, which is designed to treat hypertrophic cardiomyopathy, an inherited heart condition that impairs the heart’s ability to pump blood.
AdThe company obtained the licensing rights for BHB-1893 from Chinese drugmaker Jiangsu Hengrui Pharmaceuticals.
Financial Backing and Performance
The company has attracted significant interest from prominent life sciences investors, securing approximately $185 million from backers including a16z’s biotech fund and Patient Square Capital. Its board is chaired by Christopher Viehbacher, who also serves as the chief executive officer of Biogen Inc.
As a development-stage company, Braveheart is not yet profitable. It posted a net loss of $14.3 million on roughly $11 million in revenue during the first quarter of 2026. This compares to a net loss of $99,000 in the same period of 2025.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.